Pulmonary capillary leak syndrome with intravenous cyclosporin A in pediatric renal transplantation
- PMID: 10731056
- DOI: 10.1034/j.1399-3046.2000.00081.x
Pulmonary capillary leak syndrome with intravenous cyclosporin A in pediatric renal transplantation
Abstract
Despite frequent use of intravenous (i.v.) cyclosporin A (CsA) in the early post-operative course of transplant recipients, allergic reactions have been infrequently described. Of 134 transplants, we report four pediatric renal transplant recipients with severe reaction to i.v. CsA with pulmonary capillary leak syndrome. Pulmonary edema developed at a mean time of 3.5 h after commencement of i.v. CsA, with two patients requiring mechanical ventilation. Discontinuation of i.v. CsA and conversion to oral CsA was followed by rapid resolution of pulmonary edema, suggesting that cremaphor, the solubilizing agent in the i.v. formulation, is likely to be responsible for this adverse response. Skin prick testing with cremaphor was negative in all patients and alternative mechanisms for the cremaphor response are proposed. It is likely that inadequate mixing of the i.v. CsA solution triggered this reaction, by delivering a higher concentration of cremaphor at the start of the CsA infusion. Pulmonary edema in the early post-transplant course in the absence of obvious fluid overload should prompt the diagnosis of an i.v. CsA reaction. This life-threatening reaction is easily reversible if recognized, and can be managed easily without compromise to the allograft, by discontinuing i.v. CsA and switching early to an oral CsA formulation.
Similar articles
-
Pulmonary capillary leak syndrome associated with the use of intravenous cyclosporin.Nephrol Dial Transplant. 1996 Nov;11(11):2342-3. doi: 10.1093/oxfordjournals.ndt.a027167. Nephrol Dial Transplant. 1996. PMID: 8941609 No abstract available.
-
Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL.J Clin Oncol. 1995 Oct;13(10):2508-16. doi: 10.1200/JCO.1995.13.10.2508. J Clin Oncol. 1995. PMID: 7595701 Clinical Trial.
-
Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.Clin Pharmacokinet. 2002;41(1):59-69. doi: 10.2165/00003088-200241010-00005. Clin Pharmacokinet. 2002. PMID: 11825097 Clinical Trial.
-
Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation.Am J Kidney Dis. 1996 Oct;28(4):561-71. doi: 10.1016/s0272-6386(96)90468-0. Am J Kidney Dis. 1996. PMID: 8840947 Review.
-
Cyclosporine-induced renal dysfunction in experimental animals and humans.Kidney Int Suppl. 1995 Dec;52:S70-4. Kidney Int Suppl. 1995. PMID: 8587288 Review.
Cited by
-
Immunosuppressive drugs in paediatric liver transplantation.Paediatr Drugs. 2001;3(1):43-60. doi: 10.2165/00128072-200103010-00004. Paediatr Drugs. 2001. PMID: 11220404 Review.
-
Respiratory Distress Syndrome Associated with Erythrodermic Psoriasis.Case Rep Dermatol. 2021 Feb 4;13(1):83-88. doi: 10.1159/000511368. eCollection 2021 Jan-Apr. Case Rep Dermatol. 2021. PMID: 33708088 Free PMC article.
-
Bioequivalence and tolerability assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor ® EL.Clin Drug Investig. 2013 Jan;33(1):25-34. doi: 10.1007/s40261-012-0029-x. Clin Drug Investig. 2013. PMID: 23179472 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical